Healthcare, Pharma & Life Sciences

Cambridge – – October 14, 2026 -- TRI has released OPRA 26.2, an update to its risk-based quality management (RBQM) platform that adds an AI agent, RiskIQ, to draft protocol risk assessments. The release is available from October 14, 2026.

RiskIQ drafts Critical-to-Quality assessments from uploaded protocols

RiskIQ sits in OPRA's Protocol Insights module. It analyzes an uploaded protocol and generates a first-draft assessment of Critical-to-Quality (CtQ) factors, risks and their relationships. It works from each organization's own CtQ types and risk categories rather than generic templates.

Risk managers can edit, accept or reject every suggestion before promoting the result into OPRA as the initial risk assessment. No AI-generated content enters a live study automatically. Every decision is audit-logged and exportable.

RiskIQ is also available as a standalone application that works with any RBQM platform.

Washington – October 14, 2026 -- Danaher Corporation (NYSE: DHR) has launched a collaboration with NVIDIA to combine its scientific instruments, automation technologies, laboratory workflow software and domain expertise with NVIDIA accelerated computing and AI, targeting faster movement from AI prediction to experimental evidence.

Danaher and NVIDIA build a closed loop between experiments and models

The companies aim to create a continuous learning cycle in which experimental results inform AI models and the models help design better experiments. Danaher says the goal is to reduce the time and complexity of turning an AI-generated prediction into the experimental evidence needed to act on it.

Geneva – October 14, 2026 -- MindMaze Therapeutics (SIX: MMTX) reported that home-based rehabilitation with its MindMotion platform raised total motor-training dose by a median factor of 3.0 versus usual outpatient therapy alone, with 84% of active training completed without direct therapist supervision.

The multi-site program, run with Vibra Healthcare, was presented at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The data arrive ahead of the company's MindMotion Lite launch, expected by year-end 2026.

Program covered 177 episodes across four Vibra outpatient sites

The retrospective quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with neurological conditions, primarily stroke. It had no control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision.

Dallas – October 14, 2026 -- Ten Taiwanese hospitals and health-tech companies used Taiwan Expo USA 2026 in Dallas to probe the U.S. market, arriving at stages ranging from seeking first partners to operating FDA-cleared products with American customers.

The Smart Healthcare Pavilion ran September 24–26 at the Kay Bailey Hutchison Convention Center. It was organized by the International Trade Administration (TITA) of the Ministry of Economic Affairs and implemented by the Taiwan External Trade Development Council (TAITRA). Exhibitors covered chronic-disease management, hospital AI, remote monitoring, elder care, medical computing and rehabilitation. Their shared hurdles were validation across patient populations, U.S. regulatory clearance, workflow fit and local deployment partners.

Melbourne – October 14, 2026 -- Telix Pharmaceuticals will present 20 company-related abstracts at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna on October 17-21, 2026. Twelve of them were selected for top-rated oral presentations, with the rest running as ePosters.

Three pivotal therapeutic programs lead the oral lineup

The Phase 3 IPAX BrIGHT trial of TLX101-Tx (iodofalan-131I) in recurrent glioblastoma will be presented on October 19 by Nelleke Tolboom of UMC Utrecht. The study tests the therapy with or without lomustine against lomustine alone at first recurrence. The same morning session includes the IODO-RISE study of TLX101-Tx in recurrent high-grade glioma.

Sydney – October 14, 2026 -- Osara Health has partnered with Medibank, one of Australia's largest private health insurers, to offer its Cancer Coach program to more than 4 million Medibank customers, subject to eligibility. Eligible members living with cancer can join from 14 October 2026.

Program pairs each member with a dedicated exercise physiologist coach

Each participant works one-on-one with a coach who is an exercise physiologist trained in health coaching. Coaches help members set personal health goals and give practical guidance on fatigue, sleep, physical activity, nutrition and emotional wellbeing. Participants also receive personalised education and access to the Osara Health app.

Princeton – October 14, 2026 -- EDDA Technology has been named to TIME's 2026 list of the World's Top HealthTech Companies for the second consecutive year, the surgical imaging and AI company announced.

Statista partnership ranks companies on three pillars

TIME developed the list with data and rankings provider Statista. The analysis targets health technology companies that use digital technologies to make healthcare more effective and accessible. Companies were evaluated on Financial Performance, Reputation Analysis and Online Engagement.

IQQA platform has supported more than 130,000 cases

EDDA's IQQA® platform delivers 3D analysis of CT and MR images for personalized surgical and interventional planning. It has been used in more than 130,000 cases worldwide. The platform supports transplantation, resection, interventional procedures and postoperative assessment through quantitative analysis and visualization.

Beijing – October 14, 2026 -- Likang Life Sciences, whose lead cancer vaccine candidate LK101 holds clinical trial authorization from China's NMPA (2023) and U.S. FDA IND clearance (2025), will sponsor and exhibit at the Abu Dhabi Future Health Summit 2026 on October 20–22 at the ADNEC Centre.

Likang co-founder joins October 21 oncology panel

Shannon Cheung, Co-Founder and Vice Chairman of Likang, will speak on the panel "The Future of Cancer" on October 21. The session will cover precision oncology and the translation of innovative cancer treatments into clinical practice. It forms part of the summit's Abu Dhabi Blueprints series and will examine the roles of research, investment, policy, and international collaboration in getting new therapies to patients.

New York – October 14, 2026 -- Fesarius Therapeutics will present its DermiSphereTM hDRT dermal regeneration template at Plastic Surgery The Meeting (PSTM) 2026, October 15–18 at the George R. Brown Convention Center in Houston, Texas. The company will also appear at an event hosted by ASPS Ventures, the medtech venture fund.

Fesarius schedules a one-hour scientific symposium on October 17

The session, "From Benchtop to Bedside - Advancing Dermal Regeneration with Hydrogel Technology," runs 3:30–4:30 p.m. CDT in Innovation Theater B, Exhibit Hall DE. It will cover the science and clinical application of DermiSphereTM hDRT, including its dual-density microarchitecture, recently published clinical data and surgeon experience across complex wound and reconstructive applications.

Torrington – October 14, 2026 -- Therap Services has connected smart health monitors directly to electronic health records through its Therap Connect platform, removing manual entry of vital statistics for human services agencies.

Therap Connect captures vital signs, sleep and body composition data from smart scales, sleep mats and blood pressure monitors

The platform automatically records biometric readings from connected devices, including vital signs, body composition, sleep metrics and ambient environment conditions. Therap says manual logging creates administrative delays and raises the risk of entry errors. Data goes straight into the Therap system, giving care teams immediate visibility into health trends.